4D Molecular Therapeutics, Inc.
corporate_fare Company Profile
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for FDMT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for FDMT spans 8-K, S-3, 10-Q, DEF 14A.
Recent high-impact activity:
- Q3 Loss Widens to $78M, Missing Estimates as Operating Expenses Hit $85M
- 4DMT Reports 2-Year SPECTRA Data and Details 4SIGHT Phase 3 DME Trial Design
- 4DMT Launches Phase 3 4SIGHT Trial for DME, Reports Strong 2-Year SPECTRA Data
- 4DMT Reports Q2 2026 Results, Extends Cash Runway to H2 2028
- 4D-150 Delivers Durable Two-Year Wet AMD Efficacy, Driving 87% Treatment Burden Reduction in Key Subgroup
Financial Snapshot
Short Interest & Short Volume
10.43 days to coverFINRA reported short interest of 10,897,478 shares in FDMT as of the October 30, 2026 settlement, a 5.5% decrease from the prior period — about 10.4 days to cover at its recent average daily volume. On November 20, 2026, 53.1% of FDMT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.